Boggild M D, Jenkinson S, Pistorello M, Boscaro M, Scanarini M, McTernan P, Perrett C W, Thakker R V, Clayton R N
Department of Medicine, Keele University, Stoke-on-Trent, United Kingdom.
J Clin Endocrinol Metab. 1994 Feb;78(2):387-92. doi: 10.1210/jcem.78.2.8106627.
Tumor formation may result from the activation of dominant oncogenes or by inactivation of recessive, tumor suppressor genes. The role of such mutations in the development of pituitary tumors has been studied. Tumors from 88 patients, representing the 4 major classes of adenoma, were investigated. In DNA extracted from matched leukocyte and tumor samples, allelic deletions were sought with 15 probes identifying restriction fragment length polymorphisms on chromosomes 1, 5, 10, 11, 13, 17, 20, and 22. Evidence of amplification or rearrangement of 10 recognized cellular oncogenes (N-ras, mycL1, mycN, myc, H-ras, bcl1, H-stf1, sea, kraS2, and fos) was sought in tumor DNA. Activating dominant mutations of Gs alpha were detected using the polymerase chain reaction to amplify exons 7-10 and hybridizing the product to normal and mutant allele-specific oligonucleotides. Allelic deletions on chromosome 11 were identified in 16 tumors (18%) representing all 4 major subtypes. Deletions on other autosomes were observed in less than 6% of tumors. Three adenomas had deletions on multiple autosomes, 2 of these were aggressive and recurrent. Mutations of Gs alpha were confirmed to be specific to somatotrophinomas, being identified in 36% of such tumors in this series. No evidence of amplification or rearrangement of other recognized cellular oncogenes was found. Inactivation of a recessive oncogene on chromosome 11 is an important and possibly early event in the development of the four major types of pituitary adenoma, whereas activating mutations of Gs alpha are confirmed to be specific to somatotropinomas. Two aggressive tumors were found to have multiple autosomal losses, suggesting a multistep progression in the development of tumors of this phenotype.
肿瘤形成可能源于显性癌基因的激活,或者隐性肿瘤抑制基因的失活。此类突变在垂体肿瘤发生发展中的作用已得到研究。对来自88例患者的肿瘤进行了调查,这些肿瘤代表了4种主要类型的腺瘤。在从匹配的白细胞和肿瘤样本中提取的DNA中,使用15个探针寻找等位基因缺失,这些探针可识别1号、5号、10号、11号、13号、17号、20号和22号染色体上的限制性片段长度多态性。在肿瘤DNA中寻找10种公认的细胞癌基因(N-ras、mycL1、mycN、myc、H-ras、bcl1、H-stf1、sea、kraS2和fos)扩增或重排的证据。使用聚合酶链反应扩增外显子7-10,并将产物与正常和突变等位基因特异性寡核苷酸杂交,以检测Gsα的激活显性突变。在代表所有4种主要亚型的16个肿瘤(18%)中发现了11号染色体上的等位基因缺失。在不到6%的肿瘤中观察到其他常染色体上的缺失。3个腺瘤在多个常染色体上有缺失,其中2个具有侵袭性且复发。已证实Gsα突变是生长激素腺瘤特有的,在本系列此类肿瘤中占36%。未发现其他公认细胞癌基因扩增或重排的证据。11号染色体上隐性癌基因的失活是4种主要类型垂体腺瘤发生发展中的一个重要且可能早期的事件,而Gsα的激活突变已证实是生长激素腺瘤特有的。发现2个侵袭性肿瘤有多个常染色体缺失,提示这种表型肿瘤的发生发展存在多步骤进展。